acoramidis 356 MG Oral Tablet [Attruby]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
acoramidis 356 MG Oral Tablet [Attruby]
356 MG · Oral Tablet · oral
A form of acoramidis →
acoramidis 356 MG Oral Tablet [Attruby] — Other cardiac preparations. INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM
![acoramidis 356 MG Oral Tablet [Attruby]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913552ef-875d-4cb7-bf05-a7d20a394c38&name=att00-0005-01.jpg)
Active ingredient
Classification
Other cardiac preparations
Drug interactions
Acoramidis has several drug interactions that may affect its metabolism and the metabolism of other drugs.
- majorUGT inducers — decreased acoramidis exposure
- majorstrong CYP3A inducers — decreased acoramidis exposure
- moderatesensitive CYP2C9 substrates — increased CYP2C9 substrate concentrations
Real-world adverse events (FAERS)
Diarrhoea45Fatigue16Dizziness15Abdominal Discomfort14Blood Creatinine Increased12Nausea11Asthenia10Dyspnoea10
Indications
INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )
Dosage
DOSAGE AND ADMINISTRATION The recommended dosage of ATTRUBY is 712 mg orally twice daily. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of ATTRUBY is 712 mg orally twice daily (with or without food). Swallow tablets whole; do not cut, crush, or chew.
Contraindications
CONTRAINDICATIONS None. None. ( 4 ) To report SUSPECTED ADVERSE REACTIONS, contact BridgeBio Pharma Inc. at 1-844-550-2246 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Mechanism of action
Mechanism of Action Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.
Indicated ICD-10 codes
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication